Anakinra
IL-1 receptor antagonist
- Response rate
- 76.5% complete response
- Onset
- 2-3 days
- Route
- SC 100mg daily
- Line
- 2nd
- IgM effect
- Normalises SAA/CRP
Evidence summary
EMA-approved for FMF. First-line biologic for colchicine-resistant or intolerant patients. RCT showed significant attack reduction (1.7 vs 3.5 attacks/month, P=0.037). Rapid and persistent suppression of symptoms. Complete response in 76.5% of patients in systematic review. Requires daily subcutaneous injection.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Central effector cytokine | Elevated | established |